STAT

Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more ...
STAT

Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more

The FDA concluded that UniQure's experimental Huntington’s treatment was not providing benefit for patients based on existing clinical data ...

Pfizer CEO flags issues with FDA's vaccine leadership

Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad.

Pfizer-backed Priovant wins FDA priority review for lead asset

Pfizer (PFE)-backed Priovant Therapeutics wins U.S. FDA's priority review for skin disorder therapy with a targeted action ...
Seeking Alpha

Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
Nasdaq

Pfizer Gets FDA Priority Review For Expanded Use Of HYMPAVZI

(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer CEO flags concerns with US FDA's vaccine leadership

By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...